Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
- Written by Media Outreach
- Heidelberg Pharma grants Huadong exclusive license to develop and commercialize HDP-101 and HDP-103 in Asia[1] (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD 930 million (EUR 825 million)
- Huadong will also participate in a rights issue and acquire a percentage of...
Read more: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment














